News

The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company’s DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.

Uricase-PEG 20 is a pegylated form of the enzyme uricase (urate oxidase) that has previously completed a single dose Phase I trial and is being developed for the

The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication.

The study is designed to evaluate efficacy of PH-10 in a total of 20 subjects with mild to severe forms of the disease. In the study, subjects will

The Sunshine Act requires drug and device manufacturers to disclose to the Secretary of Health and Human Services (HHS), on a quarterly basis, anything of value given to

The resulting ‘Sentinel System’ is said to strengthen FDA’s ability to track how drugs and medical products perform once they go on the market. Ultimately, this system is

In addition, Isis has the potential to receive portions of future milestone and royalty payments. According to the company, this transaction further emphasizes the value of Isis’s innovation

Watson is seeking marketing approval of this novel transdermal gel of oxybutynin hydrochloride for the treatment of overactive bladder (OAB). Oxybutynin chloride topical gel (OTG) is a clear,

Scientists plan to use the system as a platform for genotyping, clinical genotyping, DNA methylation and quantitative gene expression (QGE) analyses. Garry Cutting, director of the DNA Diagnostic